drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An anti–folate receptor alpha (FRα) antibody-drug conjugate administered IV every 3 weeks. The monoclonal antibody binds FRα on tumor cells, is internalized via FRα-mediated endocytosis, and releases a cytotoxic payload intracellularly (with potential bystander effect) to induce tumor-cell death, targeting FRα-overexpressing epithelial tumors in recurrent gynecologic cancers.
nci_thesaurus_concept_id
C191851
nci_thesaurus_preferred_term
Opugotamig Olatansine
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of opugotamig, an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of folate receptor alpha (FRa; FolRa; FOLR1) that is conjugated, via a cleavable peptide linker, to the cytotoxic maytansinoid derivative DM21, with potential antineoplastic activity. Upon administration of opugotamig olatansine, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon cellular uptake and internalization, DM21 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of tumor cells. FRa is a glycosylphosphatidylinositol-linked cell surface glycoprotein, that is widely expressed in certain cancers while its expression is limited in normal tissues.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
IMGN151 (opugotamig olatansine) is a biparatopic monoclonal antibody targeting folate receptor alpha (FRα) conjugated via a cleavable linker to the maytansinoid DM21 (a microtubule inhibitor). After binding FRα on tumor cells, the ADC is internalized and the payload is released intracellularly, binding tubulin to disrupt microtubule dynamics, leading to cell-cycle arrest and tumor-cell death, with potential bystander killing of adjacent cells.
drug_name
IMGN151
nct_id_drug_ref
NCT05527184